Eton reports FDA application submission for ET-900 Phase 2 spasm trial
ETON•Eton Pharmaceuticals announced an FDA investigational new drug application submission for a Phase 2 trial of ET-900 for refractory epileptic spasms. The University of Chicago-sponsored study may enroll up to 20 patients ages 2–18, with initial dosing planned for the first quarter of 2027.
1. Trial application submitted
Eton Pharmaceuticals announced an FDA investigational new drug application submission for a University of Chicago-sponsored Phase 2 trial of ET-900 targeting refractory epileptic spasms. The study targets up to 20 patients ages 2–18, with initial dosing planned for the first quarter of 2027; Eton retains commercial rights to ET-900 under a patent license from Baylor College of Medicine.
